-+ 0.00%
-+ 0.00%
-+ 0.00%

Stemtech Q2 FY26 net loss narrows 1.32% to $292,358; net sales fall 9.8% to $629,312

PUBT·08/14/2026 20:49:38
Listen to the news
Stemtech Q2 FY26 net loss narrows 1.32% to $292,358; net sales fall 9.8% to $629,312
  • Stemtech posted a net loss of USD 292,358 for Q2 ended June 30, 2026, narrowing from USD 296,280 a year earlier.
  • Net sales fell 9.8% to USD 629,312 on constrained product availability across key lines that limited distributor order fulfillment.
  • Operating loss narrowed to USD 125,567 from USD 300,988 as operating expenses dropped to USD 591,240 from USD 853,004.
  • Gross margin slid 5.1 percentage points to 74% as mix worsened, with fixed fulfillment and freight costs weighing.
  • February launch of the Stemtech BioSciences e-commerce platform targets broader retail distribution and greater direct consumer access.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stemtech Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006490), on August 14, 2026, and is solely responsible for the information contained therein.